Joel Lewis, President and CEO at GALECTIN THERAPEUTICS INC (GALT), sold 14,000 shares at $6.36 ($89K) on 2025-09-12, disclosed to the SEC on 2025-09-15.
Scheduled sale ($89k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| GALT | SELL | 2025-11-19 | $231K | — | Filing → |
| GALT | SELL | 2025-11-12 | $11K | — | Filing → |
| GALT | SELL | 2025-11-07 | $1K | — | Filing → |